title: Clinical Efficacy of Ertapenem for Recurrent Cystitis Caused by Multidrug-Resistant Extended-Spectrum β-Lactamase-Producing Escherichia coli in Female Outpatients.
abstract: OBJECTIVE
  To evaluate the clinical outcomes of ertapenem administered as an outpatient parenteral antibiotic therapy for intractable cystitis caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli.
  
  
  METHODS
  We retrospectively reviewed a case series of 3 years of therapeutic experience with ertapenem for intractable recurrent cystitis caused by ESBL-producing E. coli. Ertapenem 1 g/d was parenterally administered to the patients on an outpatient basis until the acquisition of symptomatic improvement and negative conversion of urine culture. Demographic and clinical characteristics of patients, antimicrobial resistance, and clinical response data were analyzed from the patients' medical records.
  
  
  RESULTS
  During the course of this study, a total of 383 patients were diagnosed with cystitis, and 24 of them showed ESBL-producing E. coli (6.26%). The mean treatment duration of all patients was 8.5 days. The early clinical and microbiological cure rates 0 to 7 days after the end of treatment were 91.7% (22/24) and 90.9% (20/22), respectively. The late clinical and microbiological cure rates 4 to 6 weeks after the end of treatment were 72.2% (13/18) at both time points.
  
  
  CONCLUSIONS
  Parenteral ertapenem treatment can be an effective and well-tolerated treatment option for intractable recurrent cystitis by multidrug-resistant ESBL-producing E. coli.
authors.affiliation: Department of Urology, Chosun University School of Medicine, Gwangju, Korea.
authors.forename: Sungmin
authors.initials: S
authors.lastname: Song
authors.affiliation: Department of Urology, Chosun University School of Medicine, Gwangju, Korea.
authors.forename: Chulsung
authors.initials: C
authors.lastname: Kim
authors.affiliation: Department of Urology, Chosun University School of Medicine, Gwangju, Korea.
authors.forename: Donghoon
authors.initials: D
authors.lastname: Lim
keywords: Bacterial multiple drug resistance; Beta-lactams; Cystitis; Ertapenem; Escherichia coli
references.citation: Int J Antimicrob Agents. 2008 Feb;31 Suppl 1:S15-8
references.pmid: 18096373
references.citation: Arch Intern Med. 2008 Sep 22;168(17):1897-902
references.pmid: 18809817
references.citation: Int J Antimicrob Agents. 2009 Dec;34(6):585-8
references.pmid: 19748234
references.citation: Ann Acad Med Singap. 2008 Oct;37(10):831-4
references.pmid: 19037516
references.citation: Diagn Microbiol Infect Dis. 2011 May;70(1):150-3
references.pmid: 21398070
references.citation: Ann Pharmacother. 2007 Sep;41(9):1427-35
references.pmid: 17666573
references.citation: J Antimicrob Chemother. 2005 Jul;56(1):52-9
references.pmid: 15917288
references.citation: Aust Fam Physician. 2010 May;39(5):295-8
references.pmid: 20485716
references.citation: Lancet Infect Dis. 2008 Mar;8(3):159-66
references.pmid: 18291338
references.citation: Clin Infect Dis. 2011 Mar 1;52(5):e103-20
references.pmid: 21292654
references.citation: J Infect Chemother. 2011 Jun;17(3):440-6
references.pmid: 21140281
references.citation: Clin Infect Dis. 1999 Oct;29(4):745-58
references.pmid: 10589881
references.citation: Chin Med J (Engl). 2002 Oct;115(10):1479-82
references.pmid: 12490091
references.citation: Ann Pharmacother. 2008 Feb;42(2):207-12
references.pmid: 18230703
references.citation: J Pak Med Assoc. 2010 Jan;60(1):55-9
references.pmid: 20055283
references.citation: Clin Microbiol Infect. 2008 Jan;14 Suppl 1:175-80
references.pmid: 18154543
references.citation: Antimicrob Agents Chemother. 1997 Aug;41(8):1830-1
references.pmid: 9257772
references.citation: Clin Infect Dis. 2006 Apr 15;42 Suppl 4:S164-72
references.pmid: 16544267
references.citation: Int J Antimicrob Agents. 2007 Jan;29(1):62-5
references.pmid: 17189097
references.citation: Int J Antimicrob Agents. 2012 Dec;40(6):554-6
references.pmid: 23063743
references.citation: Can J Urol. 2001 Jun;8 Suppl 1:6-12
references.pmid: 11442991
references.citation: Int J Antimicrob Agents. 2001 Apr;17(4):343-8
references.pmid: 11295419
references.citation: Lancet Infect Dis. 2010 Jan;10(1):43-50
references.pmid: 20129148
references.citation: J Antimicrob Chemother. 2010 Jul;65(7):1510-3
references.pmid: 20460397
references.citation: Clin Infect Dis. 2006 Apr 1;42(7):935-7
references.pmid: 16511755